FDA Grants Interchangeable Designation to Pfizer ’s Biosimilar Abrilada

NEW YORK, October 5, 2023– Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has designated Abrilada™ (adalimumab-afzb) as an interchangeable biosimilar to Humira® (adalimumab). The...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news